Edition:
India

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

2,745JPY
11:30am IST
Change (% chg)

¥-31 (-1.12%)
Prev Close
¥2,776
Open
¥2,788
Day's High
¥2,801
Day's Low
¥2,703
Volume
349,300
Avg. Vol
382,883
52-wk High
¥3,262
52-wk Low
¥1,715

Latest Key Developments (Source: Significant Developments)

Mesoblast And JCR Pharmaceuticals Expand Japan License Agreement
Tuesday, 11 Jun 2019 

June 11 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>::MESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN.MESOBLAST LTD - EXPANDED ITS PARTNERSHIP WITH JCR PHARMACEUTICALS CO. LTD. IN JAPAN.MESOBLAST LTD - DEAL FOR USE OF MESENCHYMAL STEM CELLS (MSCS) FOR TREATMENT OF NEWBORNS WHO LACK SUFFICIENT BLOOD SUPPLY AND OXYGEN TO BRAIN.MESOBLAST LTD - DEAL FOR AGREEMENT HAS NOW BEEN FURTHER EXPANDED TO PROVIDE JCR WITH RIGHTS TO SELL TEMCELL FOR HIE.MESOBLAST LTD - DEAL FOR JCR PLANS TO INITIATE A CLINICAL TRIAL OF TEMCELL IN NEWBORNS WITH HIE IN JULY 2019.  Full Article

Photo

AstraZeneca to supply Japan with COVID-19 vaccine thru JCR Pharma output, imports

LONDON AstraZeneca said on Friday JCR Pharma will help make a portion of its potential COVID-19 vaccine in Japan and it will import shots as part of its deal to supply the Asian nation with up 120 million doses from early 2021.